Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives
TipRanksMar 20 17:56
Exagen's Strong Q4 Performance and Positive Outlook Justify Buy Rating
TipRanksMar 19 07:05
Exagen (XGN) Receives a Buy From BTIG
TipRanksJan 2 22:55
Exagen (XGN) Gets a Buy From BTIG
TipRanksDec 31, 2023 18:28
Exagen (XGN) Gets a Buy From Cantor Fitzgerald
TipRanksNov 14, 2023 20:58
Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Milestone Pharmaceuticals (MIST)
TipRanksNov 14, 2023 10:30
Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target
BenzingaSep 27, 2023 00:02
Exagen Analyst Ratings
BenzingaSep 27, 2023 00:01
Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target
BenzingaAug 22, 2023 23:55
Exagen Analyst Ratings
BenzingaAug 22, 2023 23:54
Cantor Fitzgerald Reaffirms Their Buy Rating on Exagen (XGN)
TipRanksMay 17, 2023 00:25
Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target
BenzingaMay 16, 2023 20:39
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Exagen (XGN)
TipRanksMay 16, 2023 19:10
BTIG Adjusts Price Target on Exagen to $5 From $6, Maintains Buy Rating
MT NewswiresMar 22, 2023 20:48
BTIG Maintains Buy on Exagen, Lowers Price Target to $5
BenzingaMar 22, 2023 20:17
BTIG Keeps Their Buy Rating on Exagen (XGN)
TipRanksMar 22, 2023 09:31
BTIG Adjusts Exagen's Price Target to $7 From $10, Keeps Buy Rating
MT NewswiresNov 17, 2022 21:19
Exagen Analyst Ratings
Benzinga Analyst RatingsNov 17, 2022 20:06
Canaccord Genuity Cuts Price Target on Exagen to $7 From $8, Affirms Buy Rating
MT NewswiresNov 15, 2022 22:02
Exagen Analyst Ratings
Benzinga Analyst RatingsNov 15, 2022 20:37
No Data
No Data